Valuation : BLS Pharmaceuticals Limited

Market Cap 21Cr 15Cr 13Cr 12Cr 11Cr 21Cr 1.46TCr 146.53Cr 57Cr 737.51Cr 57Cr 56Cr 2.45TCr P/E 2024
-0.72x
P/E 2025 17.8x
Enterprise Value 21Cr 15Cr 13Cr 12Cr 11Cr 21Cr 1.42TCr 142.31Cr 56Cr 716.28Cr 56Cr 55Cr 2.38TCr EV / Sales 2024
1.03x
EV / Sales 2025 2.82x
Free-Float
45.27%
Yield 2024 *
-
Yield 2025 -
1 day+1.66%
1 week-2.65%
Current month+13.58%
1 month+13.58%
3 months+17.95%
6 months+53.33%
Current year+119.05%
1 week 0.9
Extreme 0.9
0.96
1 month 0.79
Extreme 0.79
0.96
Current year 0.36
Extreme 0.36
1.1
1 year 0.33
Extreme 0.33
1.1
3 years 0.04
Extreme 0.04
1.1
5 years 0.04
Extreme 0.04
1.1
10 years 0.04
Extreme 0.04
1.4
Manager TitleAgeSince
Chief Executive Officer - 19/05/2023
Director of Finance/CFO 72 01/09/2016
Chief Operating Officer - -
Director TitleAgeSince
Chairman 67 05/12/2012
Director/Board Member 72 30/06/2022
Director/Board Member - 19/05/2023
Date Insider Type Main position Quantity % Market Cap.
14/05/26 Buy 50,00,000 0.2202%
14/05/26 Fiscal year 50,00,000 0.2202%
22/03/26 Buy

Chief Executive Officer

18,00,000 0.0804%
Change 5-day change 1-year change 3-year change Capi.($)
+1.66%-2.65%+58.62%+666.67% 15Cr
-0.78%-1.42%+2.49%+22.78% 5.05TCr
-6.00%-0.75%+442.41%+544.39% 4.46TCr
-0.24%+0.74%+38.69%+18.02% 4.31TCr
-1.55%-2.07%+23.08%+81.47% 4.17TCr
-0.31%-0.83%+16.15%+51.42% 3.32TCr
-1.79%-3.24%+27.00%+129.56% 1.68TCr
-0.58%-2.12% - - 1.63TCr
-0.88%-0.66%+11.60%+27.75% 1.46TCr
-1.66%-1.25%+78.59%+46.66% 1.39TCr
Average -1.21%-1.22%+77.63%+176.52% 2.75TCr
Weighted average by Cap. -1.70%-1.06%+95.69%+133.94%

Financials

2024 2025
Net sales 96.43L 69.18L 59.61L 55.89L 51.02L 96.12L 66Cr 6.63Cr 2.59Cr 33Cr 2.6Cr 2.54Cr 110.67Cr 2.93Cr 2.1Cr 1.81Cr 1.7Cr 1.55Cr 2.92Cr 200.78Cr 20Cr 7.86Cr 101.35Cr 7.89Cr 7.72Cr 336.06Cr
Net income -1.33Cr -95.6L -82.38L -77.24L -70.51L -1.33Cr -91Cr -9.16Cr -3.58Cr -46Cr -3.59Cr -3.51Cr -152.94Cr 49.01L 35.16L 30.3L 28.41L 25.93L 48.86L 34Cr 3.37Cr 1.32Cr 17Cr 1.32Cr 1.29Cr 56Cr
Net Debt -3L -2L -2L -2L -2L -3L -2.18Cr -21.84L -9L -1.1Cr -9L -8L -3.64Cr -61.34L -44.01L -37.92L -35.56L -32.46L -61.15L -42Cr -4.22Cr -1.65Cr -21Cr -1.65Cr -1.62Cr -70Cr
Logo BLS Pharmaceuticals Limited
BLS Pharmaceuticals Limited, formerly Bioxyne Limited, is an Australia-based international consumer health and pharmaceutical company. The Company is focused on health and wellness products, psychotropic and investigational medicines. The Company operates through three segments: Wholesale PCC/USA, Consumer Health Products UK/ EU/JPN, and Pharmaceuticals AUS. Its subsidiary, Breathe Life Sciences (BLS) manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabidiol (CBD), cannabis extracts, vitamins, manuka honey, skin care products and mushroom complexes. BLS operates in Australia, the United Kingdom, Japan, and Europe with four accredited manufacturing facilities across four countries: Japan, Australia, the United Kingdom, and Czechia. The Company directs the sales arm and has developed a range of functional food products containing ingredients sourced exclusively from New Zealand and sold in Asia.
Employees
-
Date Price Change Volume
28/26/28 A$0.9200 +1.66% 2,23,040
27/26/27 A$0.9050 -2.69% 2,44,613
26/26/26 A$0.9300 +1.09% 83,677
25/26/25 A$0.9200 -1.08% 1,92,576
24/26/24 A$0.9300 -1.59% 1,20,605

Annual profits - Rate of surprise